Streetbeat News

Regulatory

AVGO

LEN

LZB

NEE

QQQ

SPY

Wall Street is showing mixed signals with tech stocks poised for a strong start, while the Dow and S&P 500 futures are slightly down. The market's direction will depend on upcoming retail sales data and Federal Reserve speeches. Analysts remain optimistic about the market's upward momentum, driven by potential Fed rate cuts and an AI-related stock rally. Key stocks in focus include La-Z-Boy, Lennar Corp, Broadcom, and NextEra Energy.

Portfolio Pulse from Shanthi Rexaline

June 18, 2024 | 11:31 am

ZNTL

Zentalis Pharmaceuticals shares are trading lower after the FDA placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:29 am

ZNTL

Trading halt status for Zentalis Pharmaceuticals (ZNTL) was updated at 7:25:00 AM ET. The company is expected to resume trading following the release of news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:25 am

PYPD

PolyPid provides an update on its SHIELD II trial, which aims to address the rising rates of surgical site infections (SSIs) post-COVID. With 250 out of 600 patients enrolled, an unblinded interim analysis will be conducted after 400 patients complete their 30-day follow-up. Top-line results are expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

STLA

Stellantis NV (NYSE:STLA) is recalling over 1 million vehicles in the U.S. due to an issue with the rearview camera image display. The recall affects various models including Dodge Durango, Chrysler Pacifica, and Jeep Grand Cherokee L. Dealers will update the radio software free of charge.

Portfolio Pulse from Anan Ashraf

June 18, 2024 | 11:17 am

ZNTL

Zentalis Pharmaceuticals announced that the FDA has placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:16 am

RGNX

Regenxbio has concluded a pre-biologics license application (BLA) meeting with the FDA for its RGX-121 treatment for Mucopolysaccharidosis Type II. The company plans to initiate a rolling BLA submission in Q3 2024, with a confirmatory trial expected to begin in H2 2025. The FDA has confirmed that the commercial bulk drug is comparable to the clinical material.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:11 am

IONS

Otsuka Pharmaceutical has obtained exclusive rights across the Asia-Pacific region for Ionis Pharmaceuticals' donidalorsen for hereditary angioedema. Ionis will receive a $20M upfront payment and milestone payments. Ionis will handle primary development, while Otsuka will manage territory-specific development, regulatory filings, and commercialization in the Asia-Pacific region and Europe.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:06 am

NVDA

SPY

The stock market has been on a record run, potentially driven by the changing presidential polling trends favoring Donald Trump. Analysts suggest that the market is pricing in a Trump victory due to his deregulation policies, which are expected to benefit Wall Street. The SPDR S&P 500 ETF Trust (SPY) and Nvidia Corp. (NVDA) are highlighted as key players in this market rally.

Portfolio Pulse from Shanthi Rexaline

June 18, 2024 | 11:02 am

ZNTL

Trading in Zentalis Pharmaceuticals (ZNTL) was halted at 6:56:04 a.m. ET pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 10:56 am